337 related articles for article (PubMed ID: 11095756)
1. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice.
Roberts CW; Galusha SA; McMenamin ME; Fletcher CD; Orkin SH
Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13796-800. PubMed ID: 11095756
[TBL] [Abstract][Full Text] [Related]
2. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
Caramel J; Medjkane S; Quignon F; Delattre O
Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
[TBL] [Abstract][Full Text] [Related]
3. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
Kuwahara Y; Wei D; Durand J; Weissman BE
Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
[TBL] [Abstract][Full Text] [Related]
4. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5.
Roberts CW; Leroux MM; Fleming MD; Orkin SH
Cancer Cell; 2002 Nov; 2(5):415-25. PubMed ID: 12450796
[TBL] [Abstract][Full Text] [Related]
5. Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53.
Ng JM; Martinez D; Marsh ED; Zhang Z; Rappaport E; Santi M; Curran T
Cancer Res; 2015 Nov; 75(21):4629-39. PubMed ID: 26363008
[TBL] [Abstract][Full Text] [Related]
6. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
[TBL] [Abstract][Full Text] [Related]
7. Integrase interactor 1 in health and disease.
Das S
Curr Protein Pept Sci; 2015; 16(6):478-90. PubMed ID: 25772157
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation.
Isakoff MS; Sansam CG; Tamayo P; Subramanian A; Evans JA; Fillmore CM; Wang X; Biegel JA; Pomeroy SL; Mesirov JP; Roberts CW
Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17745-50. PubMed ID: 16301525
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.
Wöhrle S; Weiss A; Ito M; Kauffmann A; Murakami M; Jagani Z; Thuery A; Bauer-Probst B; Reimann F; Stamm C; Pornon A; Romanet V; Guagnano V; Brümmendorf T; Sellers WR; Hofmann F; Roberts CW; Graus Porta D
PLoS One; 2013; 8(10):e77652. PubMed ID: 24204904
[TBL] [Abstract][Full Text] [Related]
10. Complementation analyses suggest species-specific functions of the SNF5 homology domain.
Bonazzi V; Medjkane S; Quignon F; Delattre O
Biochem Biophys Res Commun; 2005 Oct; 336(2):634-8. PubMed ID: 16154112
[TBL] [Abstract][Full Text] [Related]
11. Novel germ-line deletion of SNF5/INI1/SMARCB1 gene in neonate presenting with congenital malignant rhabdoid tumor of kidney and brain primitive neuroectodermal tumor.
Kusafuka T; Miao J; Yoneda A; Kuroda S; Fukuzawa M
Genes Chromosomes Cancer; 2004 Jun; 40(2):133-9. PubMed ID: 15101046
[TBL] [Abstract][Full Text] [Related]
12. RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1.
Caramel J; Quignon F; Delattre O
Cancer Res; 2008 Aug; 68(15):6154-61. PubMed ID: 18676838
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
Kim KH; Roberts CW
Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
[TBL] [Abstract][Full Text] [Related]
14. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
15. Translocation (1;22)(p36;q11.2) with concurrent del(22)(q11.2) resulted in homozygous deletion of SNF5/INI1 in a newly established cell line derived from extrarenal rhabdoid tumor.
Misawa A; Hosoi H; Imoto I; Iehara T; Sugimoto T; Inazawa J
J Hum Genet; 2004; 49(10):586-589. PubMed ID: 15378398
[TBL] [Abstract][Full Text] [Related]
16. Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex.
Klochendler-Yeivin A; Picarsky E; Yaniv M
Mol Cell Biol; 2006 Apr; 26(7):2661-74. PubMed ID: 16537910
[TBL] [Abstract][Full Text] [Related]
17. Comparative molecular genetic analysis of simian and human HIV-1 integrase interactor INI1/SMARCB1/SNF5.
Pyeon D; Price L; Park IW
Arch Virol; 2015 Dec; 160(12):3085-91. PubMed ID: 26350979
[TBL] [Abstract][Full Text] [Related]
18. The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells.
Albanese P; Belin MF; Delattre O
Eur J Cancer; 2006 Sep; 42(14):2326-34. PubMed ID: 16908131
[TBL] [Abstract][Full Text] [Related]
19. Congenital Disseminated Extrarenal Malignant Rhabdoid Tumor.
Boudjemaa S; Petit A; Dainese L; Bourdeaut F; Lipsett J; Coulomb A
Pediatr Dev Pathol; 2015; 18(5):401-4. PubMed ID: 25751458
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific cooperation of retinoblastoma protein family and Snf5 inactivation.
Chai J; Lu X; Godfrey V; Fletcher C; Roberts CW; Van Dyke T; Weissman BE
Cancer Res; 2007 Apr; 67(7):3002-9. PubMed ID: 17409406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
